RN7SL209P

Across TCGA pan-cancer cohorts, RN7SL209P RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated RN7SL209P data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RN7SL209P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RN7SL209P expression acts as an unfavorable survival marker, although some lineages such as ESCA and PAAD show a favorable association.

CHOL, ESCA, and MESO are the cancer types where RN7SL209P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.250	0.753	<.001	72	view →
ESCA	DFS	Tertile	All	0.667	0.438	.004	66	view →
MESO	DFS	Quartile	All	0.148	0.597	<.001	18	view →
KICH	DFS	Tertile	III,IV	0.043	0.897	.045	18	view →
SKCM	DFS	Median	IV	0.187	0.763	.006	17	view →
PAAD	OS	Quartile	All	0.559	0.292	.030	11	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	9	view →
KIRC	DFS	Quartile	II,III,IV	0.424	0.667	.016	8	view →
KIRP	DFS	Quartile	IV	0.509	0.844	.004	6	view →
LUAD	DFS	Quartile	IV	0.435	0.846	.022	6	view →
LGG	DFS	Quartile	All	0.764	0.840	.028	6	view →
PCPG	DFS	Tertile	All	1.000	0.794	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

RN7SL209P–CHOL (OS)

Open the CHOL breakdown →